Use of levosimendan in cardiac surgery: An update after the LEVO-CTS, CHEETAH, and LICORN trials in the light of clinical practice

Journal of Cardiovascular Pharmacology

Volumn 71, Issue 1, 2018, Pages 1-9

  Guarracino, Fabio ^a   Heringlake, Matthias ^b   Cholley, Bernard ^c,d   Bettex, Dominique ^e   Bouchez, Stefaan ^f   Lomivorotov, Vladimir V ^g   Rajek, Angela ^h   Kivikko, Matti ^i,j   Pollesello, Piero ⁱ  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g MESHALKIN NATIONAL MEDICAL RESEARCH CENTER   (Russian Federation)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ ORION CORPORATION   (Finland)

^j JORVI HOSPITAL   (Finland)

more..

Author keywords

Cardiac surgery; Clinical trials; Levosimendan; Opinion paper; Systematic review

Indexed keywords

LEVOSIMENDAN; CARDIOVASCULAR AGENT; SIMENDAN;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FORWARD HEART FAILURE; HEART SURGERY; HIGH RISK PATIENT; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PERIOPERATIVE PERIOD; PHASE 3 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); CLINICAL DECISION MAKING; CONSENSUS; EVIDENCE BASED MEDICINE; HEART DISEASE; ORGANIZATION; PATHOPHYSIOLOGY; PATIENT SELECTION; PROCEDURES; RISK FACTOR; TREATMENT OUTCOME;

CARDIAC SURGICAL PROCEDURES; CARDIOVASCULAR AGENTS; CLINICAL DECISION-MAKING; CONGRESSES AS TOPIC; CONSENSUS; EVIDENCE-BASED MEDICINE; HEART DISEASES; HUMANS; PATIENT SELECTION; PERIOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SIMENDAN; TREATMENT OUTCOME;

EID: 85042733256     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000551     Document Type: Article

References (52)

1. Pearse RM, Moreno RP, Bauer P, et al; European Surgical Outcomes Study (EuSOS) Group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study. Lancet. 2012;380:1059-1065.
2. Coulson TG, Bailey M, Reid CM, et al. The association between perioperative acute risk change (ARC) and long-term survival after cardiac surgery. Anaesthesia. 2017;72:1467-1475.
3. Pérez Vela JL, Jiménez Rivera JJ, Alcalá Llorente MÁ, et al; en representación del Grupo ESBAGA. Low cardiac output syndrome in the postoperative period of cardiac surgery. Profile, differences in clinical course and prognosis. The ESBAGA study. Med Intensiva. 2017. doi: 10. 1016/j.medin. 2017.05.009. [epub ahead of print].
4. Algarni KD, Maganti M, Yau TM. Predictors of low cardiac output syndrome after isolated coronary artery bypass surgery: trends over 20 years. Ann Thorac Surg. 2011;92:1678-1684.
5. Hannan EL, Wu C, Bennett EV, et al. Risk index for predicting inhospital mortality for cardiac valve surgery. Ann Thorac Surg. 2007;83:921-929.
6. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;124:e652-e735.
7. Nielsen DV, Hansen MK, Johnsen SP, et al. Health outcomes with and without use of inotropic therapy in cardiac surgery: results of a propensity score-matched analysis. Anesthesiology. 2014;120:1098-1108.
8. Papp Z, Édes I, Fruhwald S, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012;159:82-87.
9. Pääkkönen K, Annila A, Sorsa T, et al. Solution structure and main chain dynamics of the regulatory domain (residues 1-91) of human cardiac troponin C. J Biol Chem. 1998;273:15633-15638.
10. Sorsa T, Pollesello P, Permi P, et al. Interaction of levosimendan with cardiac troponin C in the presence of cardiac troponin I peptides. J Mol Cell Cardiol. 2003;35:1055-1061.
11. Endoh M. Mechanisms of action of novel cardiotonic agents. J Cardiovasc Pharmacol. 2002;40:323-338.
12. Toller W, Heringlake M, Guarracino F, et al. Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion. Int J Cardiol. 2015;184:323-336.
13. Yilmaz MB, Grossini E, Silva Cardoso JC, et al. Renal effects of levosimendan: a consensus report. Cardiovasc Drugs Ther. 2013;27:581-590.
14. Cholley B, Caruba T, Grosjean S, et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA. 2017;318:548-556.
15. Landoni G, Lomivorotov VV, Alvaro G, et al; CHEETAH Study Group. Levosimendan for hemodynamic support after cardiac surgery. N Engl J Med. 2017;376:2021-2031.
16. Mehta RH, Leimberger JD, van Diepen S, et al; LEVO-CTS Investigators. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med. 2017;376:2032-2042.
17. Harrison RH, Hasselblad V, Mehta RH, et al. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth. 2013;27:1224-1232.
18. Grieshaber P, Lipp S, Arnold A, et al. Impact of prophylactic administration of levosimendan on short-term and long-term outcome in highrisk patients with severely reduced left-ventricular ejection fraction undergoing cardiac surgery-a retrospective analysis. J Cardiothorac Surg. 2016;11:162.
19. Balzer F, Treskatsch S, Spies C, et al. Early administration of levosimendan is associated with improved kidney function after cardiac surgery-a retrospective analysis. J Cardiothorac Surg. 2014;9:167.
20. Al-Shawaf E, Ayed A, Vislocky I, et al. Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery. J Cardiothorac Vasc Anesth. 2006;20:353-357.
21. Alvarez J, Taboada M, Rodríguez J, et al. Hemodynamic effects of levosimendan following cardiac surgery. Rev Esp Anestesiol Reanim. 2005;52:389-394.
22. Alvarez J, Bouzada M, Fernández AL, et al. Hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery. Rev Esp Cardiol. 2006;59:338-345.
23. De Hert SG, Lorsomradee S, Cromheecke S, et al. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg. 2007;104:766-773.
24. Eriksson HI, Jalonen JR, Heikkinen LO, et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Ann Thorac Surg. 2009;87:448-454.
25. Levin R, Porcile R, Salvagio F, et al. Levosimendan reduces mortality in post-operative low cardiac output syndrome after coronary surgery. Circulation. 2009;120 (suppl 18) :S987-S988.
26. Levin R, Degrange M, Del Mazo C, et al. Preoperative levosimendan decreases mortality and the development of low cardiac output in highrisk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp Clin Cardiol. 2012;17:125-130.
27. Lomivorotov VV, Cherniavskiy AM, Boboshko VA, et al. Levosimendan vs. intra-aortic balloon pump in high-risk cardiac surgery. Asian Cardiovasc Thorac Ann. 2011;19:154-159.
28. Järvelä K, Maaranen P, Sisto T, et al. Levosimendan in aortic valve surgery: cardiac performance and recovery. J Cardiothorac Vasc Anesth. 2008;22:693-698.
29. Lahtinen P, Pitkänen O, Pölönen P, et al. Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebocontrolled trial. Crit Care Med. 2011;39:2263-2270.
30. Leppikangas H, Järvelä K, Sisto T, et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. Br J Anaesth. 2011;106:298-304.
31. Momeni M, Rubay J, Matta A, et al. Levosimendan in congenital cardiac surgery: a randomized, double-blind clinical trial. J Cardiothorac Vasc Anesth. 2011;25:419-424.
32. Tritapepe L, De Santis V, Vitale D, et al. Preconditioning effects of levosimendan in coronary artery bypass grafting-a pilot study. Br J Anaesth. 2006;96:694-700.
33. Tritapepe L, De Santis V, Vitale D, et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth. 2009;102:198-204.
34. Severi L, Lappa A, Landoni G, et al. Levosimendan versus intra-aortic balloon pump in high-risk cardiac surgery patients. J Cardiothorac Vasc Anesth. 2011;25:632-636.
35. Lomivorotov VV, Boboshko VA, Efremov SM, et al. Levosimendan versus an intra-aortic balloon pump in high-risk cardiac patients. J Cardiothorac Vasc Anesth. 2012;26:596-603.
36. Baysal A, Yanartas M, Dogukan M, et al. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. J Cardiothorac Vasc Anesth. 2014;28:586-594.
37. Erb J, Beutlhauser T, Feldheiser A, et al. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery. J Int Med Res. 2014;42:750-764.
38. Anastasiadis K, Antonitsis P, Vranis K, et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interact Cardiovasc Thorac Surg. 2016;23:740-747.
39. Haikala H, Kaheinen P, Levijoki J, et al. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res. 1997;34:536-546.
40. Bonios MJ, Terrovitis JV, Drakos SG, et al. Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure. Int J Cardiol. 2012;159:225-229.
41. Landoni G, Biondi-Zoccai G, Greco M, et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med. 2012;40:634-646.
42. Greco T, Calabrò MG, Covello RD, et al. A Bayesian network metaanalysis on the effect of inodilatory agents on mortality. Br J Anaesth. 2015;114:746-756.
43. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2002;107:81-86.
44. Sterne JA, Gavaghan D, Egger M. Publication and related bias in metaanalysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53:1119-1129.
45. Choi SW, Lam DM. Funnels for publication bias-have we lost the plot? Anaesthesia. 2016;71:338-341.
46. Andalib A, Chetrit M, Eberg M, et al. A systematic review and metaanalysis of outcomes following mitral valve surgery in patients with significant functional mitral regurgitation and left ventricular dysfunction. J Heart Valve Dis. 2016;25:696-707.
47. Lee CT, Lin YC, Yeh YC, et al. Effects of levosimendan for perioperative cardiovascular dysfunction in patients receiving cardiac surgery: a meta-analysis with trial sequential analysis. Intensive Care Med. 2017. Available at: https://doi.org/10.1007/s00134-017-4927-5 [ePub September 7].
48. Kleber FX, Bollmann T, Borst MM, et al. Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: results of a pilot study. J Clin Pharmacol. 2009;49:109-115.
49. Ebade AA, Khalil MA, Mohamed AK. Levosimendan is superior to dobutamine as an inodilator in the treatment of pulmonary hypertension for children undergoing cardiac surgery. J Anesth. 2013;27:334-339.
50. Morelli A, Teboul JL, Maggiore SM, et al. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med. 2006;34:2287-2293.
51. Guerrero-Orriach JL, Ariza-Villanueva D, Florez-Vela A, et al. Cardiac, renal, and neurological benefits of preoperative levosimendan administration in patients with right ventricular dysfunction and pulmonary hypertension undergoing cardiac surgery: evaluation with two biomarkers neutrophil gelatinase-associated lipocalin and neuronal enolase. Ther Clin Risk Manag. 2016;12:623-630.
52. Denault A, Deschamps A, Tardif JC, et al. Pulmonary hypertension in cardiac surgery. Curr Cardiol Rev. 2010;6:1-14.